1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
OBI Pharma, Inc.

OBI Pharma, Inc.

TTPEX:4174
51.00
TWD
-2.50
(-4.67%)
-15.42EPS
3.96BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
1.06
- -
0.15
0.06
1.4
0.19
0.04
0.36
0.48
0.45
0.45
Basic EPS, GAAP
-6.07
-8.7
-11.04
-12.7
-15.72
-13.9
-14.44
-13.66
-15.3
-14.45
-9.14
-17.57
-15.61
-13.25
Free Cash Flow per Basic Share
-1.88
-6.31
-4.93
-11.71
-14.35
-10.43
-12.23
-17.79
-13.09
-17.19
-15.38
-14.85
-15.73
-13.48
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
25.26
18.78
82.09
70.49
57.92
48.98
58.14
41.85
26.87
40.26
33.01
29.01
14.35
11.3
Tangible Book Value per Share
24.29
17.9
81.44
69.96
56.46
42.51
52.75
37.36
22.93
36.93
32.38
28.53
14
11.01
Basic Weighted Avg Shares
72
77
85
87
88
88
97
101
100
112
115
131
131
115
Sales/Revenue/Turnover
- -
- -
- -
92
- -
13
6
141
19
5
42
63
59
52
Operating Margin (%)
- -
- -
- -
-1,203.69
-316,394.15
-10,703.07
-28,228.89
-1,040.47
-9,141.35
-45,059.69
-5,029.7
-3,783.67
-3,702.58
-3,145.82
Depreciation Expense
16
24
33
45
67
123
214
232
216
247
249
222
227
211
Net Income, GAAP
-439
-667
-941
-1,110
-1,379
-1,222
-1,407
-1,378
-1,531
-1,614
-1,046
-2,310
-2,053
-1,526
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1,201.15
-366,871.28
-9,162.92
-25,188.44
-978.05
-8,154.1
-34,258.46
-2,518.65
-3,685.55
-3,504.61
-2,922.86
Working Capital
1,262
893
2,231
3,782
4,645
3,689
4,815
3,646
2,527
4,813
3,001
3,027
1,230
614
LT Debt
- -
- -
- -
70
61
52
225
190
234
184
440
415
339
262
Total Equity
1,929
1,444
7,184
6,161
5,060
4,473
5,922
4,838
3,871
6,136
4,953
4,820
2,725
2,194
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-31.79
-39.55
-21.82
-16.64
-24.59
-25.98
-28.41
-28.16
-44.08
-43.93
-24.8
-60.62
-71.99
-73.93

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
176
177
184
LT Borrowings
29
11
- -
LT Finance Leases
310
275
262
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
132
132
132
Market Capitalization
7,105
4,941
3,961

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,580
1,134
841
Cash, Cash Equivalents & STI
1,186
802
497
Accounts Receivable, Net
10
2
4
Inventories
18
20
18
Total Current Liabilities
351
330
227
Payables & Accruals
- -
- -
- -
ST Debt
176
177
184
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.65%
-5.38%
-43.47%
Free Cash Flow
24.8%
5.62%
5.91%
Net Income, GAAP
13.48%
18.2%
-11.13%
Sales/Revenue/Turnover
- -
132.94%
-6.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
19
23
12
63
2025
14
13
11
21
59
2026
6
15
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-4.56
-4.72
-4.54
-6.05
-17.57
2025
-3.9
-4.97
-3.56
-6.38
-15.61
2026
-3.35
-1.5
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hui Jun Wang
Full Time Employees
260
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 3, Park Street Taipei TP Taiwan 115
IPO Date
Dec 12, 2012
Website
obipharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
OBI Pharma, Inc. (4174.TWO) is a clinical-stage global oncology company focused on developing novel cancer therapies including antibody-drug conjugates, therapeutic vaccines, and targeted prodrugs. Founded in 2002 and headquartered in Taipei, Taiwan, with subsidiaries in the United States and Australia, the company offers a pipeline featuring Adagloxad simolenin (Globo H-targeted vaccine in phase 3 for triple-negative breast cancer); OBI-833 (Globo H vaccine in phase 2 for non-small cell lung cancer); OBI-3424 (AKR1C3-targeted small-molecule prodrug in phase 2 for hepatocellular carcinoma and acute lymphocytic leukemia); OBI-992 and OBI-902 (TROP2-targeted ADCs in phase 1/2 for advanced solid tumors); OBI-999 (Globo H ADC); OBI-904 (Nectin-4 ADC); Trastuzumab-ADC (HER2-targeted); OBI-888 (Globo H monoclonal antibody); and bispecific ADCs in discovery, powered by proprietary GlycOBI, HYPrOBI, and ThiOBI enabling platforms for site-specific conjugation. OBI Pharma targets unmet needs in breast, ovarian, gastric, lung, liver, prostate, esophageal, and cholangiocarcinoma across global markets. Recent developments include US FDA Orphan Drug Designation for OBI-902 in cholangiocarcinoma (November 2025); initiation of phase 1/2 trials for OBI-902 (August 2025); technology collaboration with AP Biosciences for next-generation bispecific ADCs (September 2025); ADC partnership with TegMine Therapeutics utilizing GlycOBI and TegMiner technologies (June 2025); marketing agreement with GlyTech to expand GlycOBI outreach in Japan (December 2024); unveiling of ThiOBI and HYPrOBI platforms at AACR (April 2025); strategic pivot to prioritize ADC products and out-licensing following Globo H program termination (June 2025); and awards for most promising ADC clinical candidate and immunotherapy pipeline (March 2025).